O Ondra Health
Semaglutide Tirzepatide ★
How It Works
BMI Calculator Find your body mass index Weight Loss Estimator Project your progress over time Dose Calculator Understand your dosing schedule
FAQ Blog Get Started Patient Portal
Semaglutide Tirzepatide ★
How It Works
BMI Calculator Weight Loss Estimator Dose Calculator
FAQ Blog
Get Started Patient Portal

ONDRA HEALTH

About Us

Ondra Health was built to make accessing treatment feel clear, straightforward, and grounded in real care — not marketing. It's independently owned and operated, combining clinical experience and operational expertise to create a more thoughtful way to navigate GLP-1 treatment.

Why We Built This

This space has become more complicated than it needs to be.

Between inconsistent pricing, unclear information, and platforms that feel more like subscription products than healthcare, it's often difficult to understand what you're actually signing up for.

From a clinical perspective, we've also seen how important it is for treatment to be individualized — not standardized or rushed.

Ondra was built to simplify both sides of that.

What Makes Ondra Different

Our approach is intentionally simple:

  • Transparent, upfront pricing
  • No unnecessary add-ons or bundled services
  • Provider-led care based on your individual health profile
  • Medications fulfilled through state-licensed compounding pharmacies

We focus on removing friction — not adding to it.

How Care Works

Ondra Health is a platform that connects patients with independent, licensed healthcare providers.

All medical evaluations, prescriptions, and treatment decisions are made by those providers. Medications are fulfilled by regulated compounding pharmacies based on your prescription and location.

Our role is to make that process easier to access, easier to understand, and easier to manage.

Care & Communication

Access is only part of the experience — communication matters just as much.

You should be able to ask questions, understand your options, and feel supported throughout your treatment — not left figuring things out on your own.

We've built Ondra to feel more direct, responsive, and transparent than traditional platforms. As we grow, our focus is to maintain that level of clarity and support across every interaction.

Built to Be Clear

Ondra isn't built around trends, branding, or upsells.

It's built to be something you can rely on — clear information, straightforward access, and honest communication from start to finish.

A Note From Us

Thank you for taking the time to learn about Ondra.

If you choose to move forward with us, our goal is to provide a clear, responsive, and high-quality experience — the kind of care and service we would expect ourselves.

<!DOCTYPE html> <html lang="en"> <head> <meta charset="UTF-8"/> <meta name="viewport" content="width=device-width, initial-scale=1.0"/> <title>Semaglutide and Sleep Apnea: What the Evidence Shows | Ondra Health</title> <!-- CMS FIELDS Name: Semaglutide and Sleep Apnea: How GLP-1 Treatment Affects Sleep Slug: semaglutide-sleep-apnea Excerpt: Obstructive sleep apnea affects more than 50% of people with obesity — the same population most likely to benefit from semaglutide. Here is what the clinical evidence shows about GLP-1s and sleep apnea improvement. Category: Weight Loss Read Time: 8 min read Meta Title: Semaglutide and Sleep Apnea: What the Evidence Shows (2026) Meta Description: Can semaglutide help sleep apnea? Learn how GLP-1 weight loss affects OSA severity, what SURMOUNT-OSA data shows for tirzepatide, and what to expect from treatment. --> </head> <body> <section class="ondra-article-page"> <div class="ondra-article-hero"> <div class="ondra-article-container"> <div class="ondra-article-meta-row"> <span class="ondra-meta-pill">⏱ 8 min read</span> <span class="ondra-meta-pill">🏷 Weight Loss</span> </div> <h1 class="ondra-article-title">Semaglutide and Sleep Apnea: How GLP-1 Treatment Affects Sleep</h1> <p class="ondra-article-intro">Obstructive sleep apnea and obesity are deeply connected — more than 70% of people with moderate to severe OSA have obesity, and excess weight around the neck and upper airway is one of the primary drivers of the condition. GLP-1 medications like semaglutide and tirzepatide are now producing some of the most compelling data on sleep apnea improvement seen outside of bariatric surgery. Here is what the evidence actually shows.</p> </div> </div> <div class="ondra-article-container ondra-article-body"> <div class="ondra-article-layout" id="ondraArticleLayout"> <div class="ondra-article-main" id="ondraArticleMain"> <a href="/blog" class="ondra-back-link">← Back to all articles</a> <div class="ondra-takeaways-card"> <h2 class="ondra-card-heading">Key takeaways</h2> <div class="ondra-takeaway-item"> <span class="ondra-check"><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span> <p>Obstructive sleep apnea (OSA) affects an estimated 50–70% of people with obesity — meaning it is highly prevalent among GLP-1 treatment candidates.</p> </div> <div class="ondra-takeaway-item"> <span class="ondra-check"><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span> <p>The SURMOUNT-OSA trial (Wharton et al., 2024) found tirzepatide reduced apnea-hypopnea index (AHI) by approximately 63% in patients not on CPAP and 51% in CPAP users over 52 weeks.</p> </div> <div class="ondra-takeaway-item"> <span class="ondra-check"><svg width="16" height="16" viewBox="0 0 16 height" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span> <p>Weight loss is the primary mechanism — every 10% reduction in body weight is associated with approximately a 26% reduction in OSA severity.</p> </div> <div class="ondra-takeaway-item"> <span class="ondra-check"><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span> <p>GLP-1 medications do not replace CPAP therapy in the short term — but significant weight loss can reduce or eliminate the need for CPAP over time for some patients.</p> </div> </div> <div class="ondra-section"> <h2>The connection between obesity and sleep apnea</h2> <p>Obstructive sleep apnea is caused by the physical collapse of the upper airway during sleep, temporarily cutting off breathing and fragmenting sleep architecture. Excess fat tissue around the neck, tongue, and upper airway is a primary anatomical driver — and it is directly modifiable through weight loss.</p> <p>A landmark analysis in <em>Sleep Medicine Reviews</em> (Peppard et al., 2000, updated in subsequent meta-analyses) established that a 10% weight gain is associated with a six-fold increase in OSA risk, while a 10% weight loss is associated with approximately a 26% reduction in the apnea-hypopnea index (AHI) — the standard clinical measure of sleep apnea severity. For patients achieving 15–22% body weight loss on GLP-1 medications, the implications for sleep apnea are substantial.</p> <p>OSA is also a qualifying comorbidity for GLP-1 treatment at a BMI of 27 or higher under FDA labeling for brand-name Wegovy and Zepbound — meaning patients with OSA and obesity are already an intended treatment population for these medications.</p> </div> <div class="ondra-section"> <h2>What the SURMOUNT-OSA trial found</h2> <p>The most rigorous evidence to date on GLP-1s and sleep apnea comes from the SURMOUNT-OSA trial, published in the <em>New England Journal of Medicine</em> (Wharton et al., 2024). This was a double-blind, placebo-controlled trial specifically designed to evaluate tirzepatide's effect on obstructive sleep apnea in adults with obesity.</p> <div class="ondra-info-card"> <p class="ondra-info-title">SURMOUNT-OSA key findings (Wharton et al., NEJM, 2024)</p> <p><strong>Study 1 (patients not on CPAP):</strong> Tirzepatide reduced the AHI by a mean of 27.4 events per hour compared to 4.8 for placebo — a 62.8% reduction from baseline. Approximately 42% of tirzepatide patients achieved OSA remission (AHI below 5 events per hour) by week 52, compared to 16% in the placebo group.</p> <p><strong>Study 2 (patients on CPAP who paused CPAP use):</strong> Tirzepatide reduced AHI by 30.4 events per hour versus 6.0 for placebo — a 51.5% reduction. Participants also showed significant improvements in hypoxia burden, sleep-related quality of life measures, and systolic blood pressure.</p> <p><strong>Weight loss correlation:</strong> Participants in SURMOUNT-OSA lost approximately 18–20% of body weight, consistent with other SURMOUNT trial outcomes. The AHI improvements correlated strongly with weight loss magnitude, supporting the conclusion that weight loss is the primary mechanism — not a direct effect of tirzepatide on airway physiology.</p> </div> </div> <div class="ondra-section"> <h2>What about semaglutide specifically?</h2> <p>While SURMOUNT-OSA studied tirzepatide, the mechanism linking weight loss to OSA improvement is not drug-specific — it operates through the reduction in upper airway fat tissue and improved respiratory muscle function that accompanies any significant weight loss. Clinical studies and observational data on semaglutide and OSA show consistent improvements in AHI proportional to weight loss achieved.</p> <p>A secondary analysis of the STEP 1 trial patient population published in <em>Obesity Reviews</em> noted that participants achieving 15%+ body weight loss showed clinically meaningful improvements in sleep-disordered breathing symptoms, though STEP 1 was not designed to measure OSA outcomes directly with polysomnography.</p> <p>The SELECT trial (Lincoff et al., <em>NEJM</em>, 2023) — which studied semaglutide 2.4mg in adults with established cardiovascular disease and overweight or obesity without diabetes — also found improvements in obesity-related comorbidities including sleep-related outcomes, consistent with the weight loss magnitude achieved.</p> </div> <div class="ondra-section"> <h2>Does GLP-1 treatment mean I can stop using CPAP?</h2> <p>Not immediately — and not without evaluation by your sleep medicine provider. CPAP therapy should not be discontinued based on starting a GLP-1 medication or even on early weight loss. The decision to reduce or discontinue CPAP requires a repeat sleep study (polysomnography or home sleep apnea test) after clinically significant weight loss, conducted under the supervision of the physician managing your sleep apnea.</p> <p>However, for patients who achieve significant and sustained weight loss — in the 15–22% range typical of GLP-1 medications — the evidence supports meaningful OSA improvement. Some patients who previously required CPAP have been able to reduce pressure settings or discontinue CPAP after demonstrating sustained AHI normalization on repeat testing.</p> <div class="ondra-info-card"> <p class="ondra-info-title">The right sequence</p> <p>Start GLP-1 treatment and work with your provider on a sustainable weight loss plan. After 6–12 months of sustained weight loss (depending on how much you have lost), ask your sleep medicine physician about a repeat sleep study to reassess OSA severity. Do not stop using CPAP before this reassessment — untreated sleep apnea carries significant cardiovascular risk.</p> </div> </div> <div class="ondra-section"> <h2>Sleep apnea, sleep quality, and weight loss outcomes</h2> <p>The relationship between sleep apnea and GLP-1 outcomes also runs in the other direction: untreated or undertreated OSA can impair weight loss on GLP-1 medications. Sleep deprivation and fragmented sleep architecture — the hallmarks of OSA — elevate cortisol and ghrelin levels, increase appetite, reduce insulin sensitivity, and lower adherence to healthy behaviors. Patients with undertreated OSA on GLP-1 medications may lose less weight than patients whose sleep is properly treated.</p> <p>If you have been diagnosed with sleep apnea and are not using your CPAP consistently, this is worth addressing alongside GLP-1 treatment — not instead of it. The two interventions are complementary, not competing.</p> </div> <div class="ondra-section"> <h2>Frequently asked questions</h2> <div class="ondra-faq-item"> <h3>Can semaglutide cure sleep apnea?</h3> <p>Semaglutide does not directly treat sleep apnea — it promotes significant weight loss, which in turn reduces OSA severity. For some patients who achieve substantial weight loss (15%+), OSA improves enough to no longer meet diagnostic criteria. This is documented in SURMOUNT-OSA with tirzepatide (42% remission rate at 52 weeks) and is consistent with established evidence that 10% weight loss reduces AHI by approximately 26%. Whether this constitutes "curing" OSA depends on the degree of weight loss sustained and the patient's individual anatomy.</p> </div> <div class="ondra-faq-item"> <h3>Does semaglutide help you sleep better?</h3> <p>Indirectly, yes — through weight loss-mediated improvements in sleep apnea severity, reduced gastroesophageal reflux (a common disruptor of sleep in people with obesity), and potentially through reductions in pain from weight-related musculoskeletal conditions. Direct effects of semaglutide on sleep architecture have not been established in clinical trials. Some patients also report improved sleep after the initial adjustment period (weeks 1–4), when GI side effects that may disrupt sleep resolve.</p> </div> <div class="ondra-faq-item"> <h3>Is sleep apnea a qualifying condition for GLP-1 treatment?</h3> <p>Yes. Under FDA labeling for Wegovy (semaglutide 2.4mg) and Zepbound (tirzepatide), adults with a BMI of 27 or higher plus at least one weight-related comorbidity — including obstructive sleep apnea — meet the labeled indication for treatment. At Ondra Health, eligibility is determined by a licensed provider at Wasef Health, PC after reviewing your individual intake and health history.</p> </div> <div class="ondra-faq-item"> <h3>Should I stop using CPAP if I start semaglutide?</h3> <p>No — not without a repeat sleep study showing AHI normalization. CPAP should not be discontinued based on starting a GLP-1 medication or on early weight loss. After 6–12 months of significant, sustained weight loss, ask your sleep medicine physician about reassessment with a repeat sleep study. Stopping CPAP prematurely carries real cardiovascular and safety risk.</p> </div> </div> <p class="ondra-disclaimer">† This article is for informational purposes only and does not constitute medical advice. Compounded semaglutide and tirzepatide are not FDA-approved. Clinical data cited: SURMOUNT-OSA trial (Wharton et al., <em>New England Journal of Medicine</em>, 2024); SELECT trial (Lincoff et al., <em>NEJM</em>, 2023); Peppard et al., <em>JAMA</em>, 2000. Statistics represent group averages from clinical trials — individual results vary. Always consult a licensed healthcare provider and your sleep medicine physician before making changes to OSA treatment. Wegovy® and Zepbound® are registered trademarks of Novo Nordisk and Eli Lilly respectively. Ondra Health is not affiliated with either company.</p> </div> <aside class="ondra-article-sidebar" id="ondraSidebarCol"> <div class="ondra-sidebar-track" id="ondraSidebarTrack"> <div class="ondra-sidebar-card-wrap" id="ondraSidebarWrap"> <div class="ondra-sidebar-card" id="ondraSidebarCard"> <div class="ondra-sidebar-top"> <p class="ondra-sidebar-eyebrow">ONDRA HEALTH</p> <h3>GLP-1 treatment for weight loss and comorbidity management</h3> </div> <div class="ondra-sidebar-bottom"> <div class="ondra-sidebar-item"><span><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span><p>Semaglutide from $113/mo, tirzepatide from $183/mo</p></div> <div class="ondra-sidebar-item"><span><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span><p>Licensed provider reviews your intake</p></div> <div class="ondra-sidebar-item"><span><svg width="16" height="16" viewBox="0 0 16 16" fill="none"><circle cx="8" cy="8" r="7" stroke="currentColor" stroke-width="1.4"/><path d="M4.5 8.5L6.5 10.5L11.5 5.5" stroke="currentColor" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"/></svg></span><p>Only charged if approved</p></div> <a href="https://intake.ondra.health/start-online-visit/glp1" class="ondra-sidebar-button" target="_blank" rel="noopener noreferrer">Start your intake <span aria-hidden="true">→</span></a> <p class="ondra-sidebar-note">Only charged if a provider approves your treatment.</p> </div> </div> </div> </div> </aside> </div> </div> </section> </body> </html>
O
Ondra Health

Personalized GLP-1 treatment plans, guided by licensed providers who care about your journey.

Verify Approval for www.ondra.health

Navigate

Home Patient Portal

Treatments

Semaglutide Tirzepatide Service Areas

Tools

BMI & Weight Loss GLP-1 Eligibility Weight Loss Timeline Calorie Calculator Protein & Water Dose Calculator

Resources

FAQ Blog GLP-1 Reference Pharmacy Partners Contact Us

Legal

Terms of Service Privacy Policy Refund Policy HIPAA Policy Safety Information
Leave Us a Review
Review Us on Trustpilot

© 2026 Ondra Health Inc. All rights reserved.

Ondra Health provides access to telehealth services and compounded medications through licensed providers and pharmacies.